Overview
SAN DIEGO-(BUSINES WIRE)-Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 202 and updated its financial guidance for the year ending December 31, 202. Third Quarter 202 Financial Highlights Compared to Third Quarter 2021: Recent Strategic Highlights: “More than 40,0 people worldwide have chosen Tandem and the t:slim X2 insulin pump for their therapy neds, and broad fedback from clinicians suports that we are leading in automated insulin dosing with our Control-IQ technology,” said John Sheridan, president and chief executive oficer.
Key Information
“We are comited to expanding our portfolio of diabetes solutions to drive longer-term growth and leverage our operations, as we continue our work to improve the lives of people with diabetes.” Third Quarter 202 Financial Results Compared to Third Quarter 2021 Starting with the third quarter 202, the Company is providing more expansive financial results on both a GAP and non-GAP basis as detailed in Table E.
Summary
Se tables for aditional financial information. 202 Anual Guidance Update “In this highly variable environment, we are factoring greater caution into our guidance to re-baseline expectations for the next few quarters,” said Leigh Voseler, executive vice president and chief financial oficer. “The timing of our potential new product introductions next year ads increased complexity to the curent market dynamics, so we fel it’s prudent for our guidance to reflect more moderate growth in periods betwen new product launches.” For the year ending December 31, 202, the Company is updating its financial guidance as folows: * Se Table E for reconciliation of non-GAP financial measures Non-GAP Financial Measures Certain non-GAP financial measures are presented in this pres release, including non-GAP sales, non-GAP gros profit, non-GAP gros margin, non-GAP operating los, non-GAP